<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866004</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-20-0886</org_study_id>
    <nct_id>NCT04866004</nct_id>
  </id_info>
  <brief_title>Contingency Management for Cannabis Use for Persons With HIV</brief_title>
  <official_title>Feasibility and Impact of 28-days of Monitored Abstinence From Cannabis Use on Symptoms of Distress, Inflammation, and HIV Viral Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Texas Health Sciences Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility and impact of 28-days of monitored&#xD;
      abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use&#xD;
      withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use&#xD;
      cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial&#xD;
      involving a contingency management program to induce cannabis abstinence. Specifically, the&#xD;
      contingency management program will provide motivational (monetary) incentives to&#xD;
      participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this&#xD;
      pilot feasibility trial, participants will attend seven study visits. During these visits,&#xD;
      participants will complete survey questionnaires to assess sociodemographic, psychosocial,&#xD;
      and behavioral factors. In addition, participants will provide blood and urine specimens for&#xD;
      testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the&#xD;
      detection of cannabis and other drugs of abuse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained cannabis abstinence for 28-days</measure>
    <time_frame>28-days</time_frame>
    <description>Cannabis abstinence will be defined as sustained reduction in quantitative levels of 11-Nor-9-carboxy-Δ⁹-tetrahydrocannabinol (THCCOOH) for 28-days</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Marijuana</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Contingency Management - Cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Management - Cannabis</intervention_name>
    <description>Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.</description>
    <arm_group_label>Contingency Management - Cannabis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)&#xD;
&#xD;
          -  Self-report of cannabis use at least once per week in the 6-month period prior to&#xD;
             consent&#xD;
&#xD;
          -  Provide a positive urine toxicology (UTOX) screen for cannabis&#xD;
&#xD;
          -  Not seeking treatment for cannabis use&#xD;
&#xD;
          -  Willing to stop using cannabis for 28 days and attend eight study visits over six&#xD;
             weeks.&#xD;
&#xD;
          -  Ability and willingness to provide inform consent&#xD;
&#xD;
          -  English fluency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving treatment for cannabis or other drug use disorder&#xD;
&#xD;
          -  Diagnosed or receiving treatment for a current major depressive or anxiety disorder&#xD;
&#xD;
          -  Diagnosed with any current alcohol or substance use disorder (excluding nicotine)&#xD;
             using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)&#xD;
&#xD;
          -  Positive UTOX screen for opioids&#xD;
&#xD;
          -  Having a medical, psychiatric, occupational, or other condition that, in the judgment&#xD;
             of the study physician, would make participation difficult or unsafe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chukwuemeka N Okafor, PhD, MPH</last_name>
    <phone>857-225-3923</phone>
    <email>emeka_okafor@baylor.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Neurobehavioral Research on Addiction</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolanda Johnson</last_name>
      <phone>713-486-2823</phone>
      <email>rolanda.johnson@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76798</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chukwuemeka N Okafor, PhD, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor University</investigator_affiliation>
    <investigator_full_name>Emeka Okafor</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

